Pfizer Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Pfizer Corp from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
04/30/2025 | Buy Now | — | UBS | Trung Huynh67% | $24 → $25 | Maintains | Neutral | Get Alert |
04/22/2025 | Buy Now | — | Cantor Fitzgerald | Carter Gould60% | → $24 | Initiates | → Neutral | Get Alert |
04/08/2025 | Buy Now | — | UBS | Trung Huynh67% | $28 → $24 | Maintains | Neutral | Get Alert |
04/08/2025 | Buy Now | — | Goldman Sachs | Asad Haider 66% | $32 → $25 | Downgrade | Buy → Neutral | Get Alert |
03/18/2025 | Buy Now | — | Guggenheim | Vamil Divan76% | — | Reiterates | Buy → Buy | Get Alert |
03/12/2025 | Buy Now | — | Guggenheim | Vamil Divan76% | — | Reiterates | Buy → Buy | Get Alert |
02/10/2025 | Buy Now | — | Guggenheim | Vamil Divan76% | $33 → $33 | Reiterates | Buy → Buy | Get Alert |
02/05/2025 | Buy Now | — | UBS | Colin Bristow40% | $29 → $28 | Maintains | Neutral | Get Alert |
01/28/2025 | Buy Now | — | Citigroup | Andrew Baum71% | $30 → $29 | Maintains | Neutral | Get Alert |
01/08/2025 | Buy Now | — | UBS | Colin Bristow40% | $31 → $29 | Maintains | Neutral | Get Alert |
12/18/2024 | Buy Now | — | Truist Securities | Srikripa Devarakonda46% | $36 → $32 | Maintains | Buy | Get Alert |
12/11/2024 | Buy Now | — | Guggenheim | Vamil Divan76% | $35 → $33 | Maintains | Buy | Get Alert |
12/10/2024 | Buy Now | — | B of A Securities | Tim Anderson61% | → $29 | Reinstates | → Neutral | Get Alert |
11/15/2024 | Buy Now | — | Wolfe Research | Alexandria Hammond47% | → $25 | Initiates | → Underperform | Get Alert |
10/30/2024 | Buy Now | — | Morgan Stanley | Terence Flynn68% | $30 → $31 | Maintains | Equal-Weight | Get Alert |
10/25/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
10/23/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
10/17/2024 | Buy Now | — | Bernstein | Courtney Breen1% | → $32 | Initiates | → Market Perform | Get Alert |
10/11/2024 | Buy Now | — | Morgan Stanley | Terence Flynn68% | $31 → $30 | Maintains | Equal-Weight | Get Alert |
10/03/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
09/16/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
09/09/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
08/19/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
08/08/2024 | Buy Now | — | Daiwa Capital | Narumi Nakagiri23% | $28 → $34 | Upgrade | Neutral → Outperform | Get Alert |
07/31/2024 | Buy Now | — | Morgan Stanley | Terence Flynn68% | $29 → $31 | Maintains | Equal-Weight | Get Alert |
07/31/2024 | Buy Now | — | Barclays | Carter Gould60% | $30 → $32 | Maintains | Equal-Weight | Get Alert |
07/31/2024 | Buy Now | — | Wells Fargo | Mohit Bansal72% | $28 → $30 | Maintains | Equal-Weight | Get Alert |
07/31/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
07/31/2024 | Buy Now | — | UBS | Colin Bristow40% | $30 → $31 | Maintains | Neutral | Get Alert |
07/12/2024 | Buy Now | — | UBS | Colin Bristow40% | $28 → $30 | Maintains | Neutral | Get Alert |
07/10/2024 | Buy Now | — | Barclays | Carter Gould60% | $28 → $30 | Maintains | Equal-Weight | Get Alert |
07/10/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
07/01/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
06/26/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
06/20/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
06/17/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
05/02/2024 | Buy Now | — | Morgan Stanley | Terence Flynn68% | $28 → $29 | Maintains | Equal-Weight | Get Alert |
05/02/2024 | Buy Now | — | BMO Capital | Evan David Seigerman51% | $33 → $36 | Reiterates | Outperform → Outperform | Get Alert |
04/18/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
04/15/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
04/05/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
04/01/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
03/31/2024 | Buy Now | — | Morgan Stanley | Terence Flynn68% | $28 → $29 | Maintains | Equal-Weight | Get Alert |
03/22/2024 | Buy Now | — | Argus Research | David Toung71% | — | Downgrade | Buy → Hold | Get Alert |
03/04/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
03/01/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
02/23/2024 | Buy Now | — | Guggenheim | Vamil Divan76% | → $36 | Initiates | → Buy | Get Alert |
01/31/2024 | Buy Now | — | UBS | Colin Bristow40% | $29 → $28 | Maintains | Neutral | Get Alert |
01/31/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
01/17/2024 | Buy Now | — | UBS | Colin Bristow40% | $27 → $29 | Maintains | Neutral | Get Alert |
01/09/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | $45 → $45 | Reiterates | Overweight → Overweight | Get Alert |
01/04/2024 | Buy Now | — | TD Cowen | Steve Scala69% | → $32 | Downgrade | Outperform → Market Perform | Get Alert |
12/14/2023 | Buy Now | — | Wells Fargo | Mohit Bansal72% | $35 → $28 | Maintains | Equal-Weight | Get Alert |
12/14/2023 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | $75 → $45 | Maintains | Overweight | Get Alert |
12/14/2023 | Buy Now | — | Truist Securities | Robyn Karnauskas55% | $42 → $36 | Maintains | Buy | Get Alert |
12/14/2023 | Buy Now | — | UBS | Colin Bristow40% | $34 → $27 | Maintains | Neutral | Get Alert |
12/14/2023 | Buy Now | — | Barclays | Carter Gould60% | $34 → $28 | Maintains | Equal-Weight | Get Alert |
12/04/2023 | Buy Now | — | Truist Securities | Robyn Karnauskas55% | → $42 | Reiterates | Buy → Buy | Get Alert |
11/20/2023 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | → $75 | Reiterates | Overweight → Overweight | Get Alert |
11/01/2023 | Buy Now | — | Barclays | Carter Gould60% | $35 → $34 | Maintains | Equal-Weight | Get Alert |
11/01/2023 | Buy Now | — | Morgan Stanley | Terence Flynn68% | $39 → $37 | Maintains | Equal-Weight | Get Alert |
10/20/2023 | Buy Now | — | UBS | Colin Bristow40% | $36 → $34 | Assumes | Neutral → Neutral | Get Alert |
10/17/2023 | Buy Now | — | Truist Securities | Robyn Karnauskas55% | $62 → $42 | Maintains | Buy | Get Alert |
10/17/2023 | Buy Now | — | Morgan Stanley | Terence Flynn68% | $40 → $39 | Maintains | Equal-Weight | Get Alert |
10/17/2023 | Buy Now | — | Wells Fargo | Mohit Bansal72% | $39 → $35 | Maintains | Equal-Weight | Get Alert |
10/16/2023 | Buy Now | — | BMO Capital | Evan David Seigerman51% | $44 → $33 | Maintains | Outperform | Get Alert |
10/16/2023 | Buy Now | — | Citigroup | Andrew Baum71% | $42 → $35 | Maintains | Neutral | Get Alert |
10/16/2023 | Buy Now | — | JP Morgan | Chris Schott60% | $36 → $34 | Maintains | Neutral | Get Alert |
10/16/2023 | Buy Now | — | Wells Fargo | Mohit Bansal72% | $39 → $35 | Maintains | Equal-Weight | Get Alert |
10/16/2023 | Buy Now | — | Jefferies | Akash Tewari45% | $38 → $39 | Upgrade | Hold → Buy | Get Alert |
10/06/2023 | Buy Now | — | JP Morgan | Chris Schott60% | $39 → $36 | Maintains | Neutral | Get Alert |
10/02/2023 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | → $75 | Reiterates | Overweight → Overweight | Get Alert |
09/18/2023 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | → $75 | Reiterates | Overweight → Overweight | Get Alert |
09/13/2023 | Buy Now | — | Truist Securities | Robyn Karnauskas55% | → $62 | Reiterates | Buy → Buy | Get Alert |
09/05/2023 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | → $75 | Reiterates | Overweight → Overweight | Get Alert |
08/30/2023 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | → $75 | Reiterates | Overweight → Overweight | Get Alert |
08/22/2023 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | → $75 | Reiterates | Overweight → Overweight | Get Alert |
08/02/2023 | Buy Now | — | Truist Securities | Robyn Karnauskas55% | $64 → $62 | Maintains | Buy | Get Alert |
08/02/2023 | Buy Now | — | Morgan Stanley | Terence Flynn68% | $42 → $40 | Maintains | Equal-Weight | Get Alert |
08/02/2023 | Buy Now | — | BMO Capital | Evan David Seigerman51% | $45 → $44 | Maintains | Outperform | Get Alert |
07/21/2023 | Buy Now | — | Morgan Stanley | Terence Flynn68% | $43 → $42 | Maintains | Equal-Weight | Get Alert |
07/14/2023 | Buy Now | — | HSBC | Rajesh Kumar60% | → $50 | Initiates | → Buy | Get Alert |
07/11/2023 | Buy Now | — | Morgan Stanley | Terence Flynn68% | $43 → $43 | Reiterates | Equal-Weight → Equal-Weight | Get Alert |
07/11/2023 | Buy Now | — | Barclays | Carter Gould60% | $40 → $38 | Maintains | Equal-Weight | Get Alert |
06/29/2023 | Buy Now | — | Credit Suisse | Trung Huynh67% | $47 → $40 | Downgrade | Outperform → Neutral | Get Alert |
06/23/2023 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | $75 → $75 | Reiterates | Overweight → Overweight | Get Alert |
06/22/2023 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | → $75 | Reiterates | Overweight → Overweight | Get Alert |
05/17/2023 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | → $75 | Reiterates | Overweight → Overweight | Get Alert |
05/11/2023 | Buy Now | — | Daiwa Capital | Narumi Nakagiri23% | $51 → $38 | Downgrade | Outperform → Neutral | Get Alert |
05/03/2023 | Buy Now | — | Credit Suisse | Trung Huynh67% | $50 → $47 | Maintains | Outperform | Get Alert |
05/03/2023 | Buy Now | — | Barclays | Carter Gould60% | $43 → $40 | Maintains | Equal-Weight | Get Alert |
04/21/2023 | Buy Now | — | B of A Securities | Geoff Meacham63% | $50 → $45 | Maintains | Neutral | Get Alert |
04/12/2023 | Buy Now | — | Barclays | Carter Gould60% | $44 → $43 | Maintains | Equal-Weight | Get Alert |
04/10/2023 | Buy Now | — | Morgan Stanley | Terence Flynn68% | $45 → $44 | Maintains | Equal-Weight | Get Alert |
03/17/2023 | Buy Now | — | Wells Fargo | Mohit Bansal72% | $50 → $44 | Maintains | Equal-Weight | Get Alert |
03/06/2023 | Buy Now | — | Jefferies | Akash Tewari45% | → $43 | Initiates | → Hold | Get Alert |
02/07/2023 | Buy Now | — | Daiwa Capital | Narumi Nakagiri23% | → $51 | Upgrade | Neutral → Outperform | Get Alert |
02/01/2023 | Buy Now | — | Morgan Stanley | Terence Flynn68% | $53 → $45 | Maintains | Equal-Weight | Get Alert |
02/01/2023 | Buy Now | — | Cantor Fitzgerald | Louise Chen56% | → $75 | Reiterates | → Overweight | Get Alert |
02/01/2023 | Buy Now | — | Credit Suisse | Trung Huynh67% | $54 → $50 | Maintains | Outperform | Get Alert |
The latest price target for Pfizer (NYSE:PFE) was reported by UBS on April 30, 2025. The analyst firm set a price target for $25.00 expecting PFE to rise to within 12 months (a possible 3.39% upside). 36 analyst firms have reported ratings in the last year.
The latest analyst rating for Pfizer (NYSE:PFE) was provided by UBS, and Pfizer maintained their neutral rating.
The last upgrade for Pfizer Inc happened on August 8, 2024 when Daiwa Capital raised their price target to $34. Daiwa Capital previously had a neutral for Pfizer Inc.
The last downgrade for Pfizer Inc happened on April 8, 2025 when Goldman Sachs changed their price target from $32 to $25 for Pfizer Inc.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Pfizer, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Pfizer was filed on April 30, 2025 so you should expect the next rating to be made available sometime around April 30, 2026.
While ratings are subjective and will change, the latest Pfizer (PFE) rating was a maintained with a price target of $24.00 to $25.00. The current price Pfizer (PFE) is trading at is $24.18, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.